Breast Cancer Drugs Global Market Report 2024, Featuring Profiles of Key Players Novartis, AstraZeneca, Eli Lilly, Biocon, Merck and MacroGenics
December 14, 2023 11:03 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Breast Cancer Drugs Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.The breast cancer drugs market size is set to to...
Europe Breast and Prostate Cancer Diagnostics Industry is estimated to reach US$ 5,030.1 Million by 2033 Amid Growing Research on Biomarkers | FMI Study
December 11, 2023 05:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Europe breast and prostate cancer diagnostics industry is estimated to reach US$ 4,041.5 million in 2023 and US$ 5,030.1 million by 2033. Over the...
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
December 08, 2023 16:05 ET
|
Onconova Therapeutics, Inc.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Study Finds Opto-Acoustic Imaging During Neoadjuvant Therapy Correlates to Pathologic Response
December 08, 2023 14:00 ET
|
Seno Medical
San Antonio, Texas, Dec. 08, 2023 (GLOBE NEWSWIRE) -- A limited feasibility study presented at this year’s San Antonio Breast Cancer Symposium (SABCS) found that Seno Medical’s Imagio® Breast...
Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium
December 06, 2023 08:30 ET
|
Celcuity Inc.
MINNEAPOLIS, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today presented data from...
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
December 05, 2023 22:52 ET
|
Arvinas Inc.
NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
December 05, 2023 13:33 ET
|
Arvinas Inc.
– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the...
Olema Oncology Announces Palazestrant Demonstrates Attractive Combinability with CDK4/6 Inhibitors Ribociclib and Palbociclib in Phase 1b/2 Studies
December 05, 2023 12:27 ET
|
Olema Oncology
Palazestrant (OP-1250) in combination with the CDK 4/6 inhibitors, ribociclib and palbociclib, demonstrated no significant drug-drug interaction, no dose-limiting toxicities and a tolerability profile...
PreludeDx to Present New Data on the Clinical Utility of DCISionRT in Australian Patients with DCIS at the 2023 San Antonio Breast Cancer Symposium
December 05, 2023 07:00 ET
|
PreludeDx
In data presented at SABCS23, DCISionRT changed radiation therapy decisions in 41% of DCIS patients
Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium
December 01, 2023 11:02 ET
|
Celcuity Inc.
MINNEAPOLIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that an...